Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.42 |
| ▸ | PTGIR | P43119 | 7/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975370 | 0.91 | PTGIR (0.40) | GPR88PTGIRBCHECYP2C19KDM4E | |
| SCHEMBL19975274 | 0.86 | PTGIR (0.41) | GPR88PTGIRBCHECYP2C19KDM4E | |
| SCHEMBL19974931 | 0.85 | GPR88 (0.40) | GPR88 | |
| SCHEMBL19975199 | 0.83 | PTGIR (0.39) | GPR88PTGIRBCHECYP2C19ALDH1A1 | |
| SCHEMBL19974728 | 0.81 | BCHE (0.42) | PTGIRBCHEALDH1A1SLC6A2 | |
| SCHEMBL19975353 | 0.81 | BCHE (0.45) | BCHEALDH1A1SLC6A2 | |
| SCHEMBL21176166 | 0.81 | BCHE (0.46) | BCHEALDH1A1 | |
| SCHEMBL19975282 | 0.80 | PTGIR (0.38) | GPR88PTGIRCYP2C19SLC6A2 | |
| SCHEMBL19975386 | 0.76 | POLB (0.43) | ALDH1A1 | |
| SCHEMBL19975442 | 0.75 | PKM (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | GPR88 1894/4885PTGIR 540/4885BCHE 1677/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | GPR88 2316/4885PTGIR 679/4885BCHE 1540/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | GPR88 1894/4885PTGIR 540/4885BCHE 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.